Factors controlling particle size during nebulization of DNA-polycation complexes.
Pulmonary gene therapy has the potential to treat or cure respiratory diseases such as cystic fibrosis. Much work has focused on the delivery of genes to the lung using viral vectors with varying degrees of success. Viral vectors are problematic and undesirable for use in the lung because they can provoke an acute immune response. This study has focused on the characterization of nonviral, polymer-based gene vectors for use with nebulizers. Calf thymus DNA has been used as a model, and was complexed with each of the three polycations; 22 kDa linear polyethyleneimine, 25 kDa branched polyethyleneimine, and 29.5 kDa polylysine using water, glucose solution, and phosphate-buffered saline (PBS) as carrier liquids. Fourier transform infrared spectroscopy has shown that the DNA retains the B form during the complex formation. The complexes prepared at N:P ratios of 10, have been nebulized using a vibrating plate nebulizer and the particle size and Zeta potentials measured before and after nebulization. The particle size distributions of the DNA complexes prepared in water and glucose solution were unimodal before and after nebulization with a small increase in particle size following nebulization. Choice of complexing polymer is shown to have only a small effect on particle size with the dominant effect coming from the ionic character of the dispersion fluid. Complexes prepared in PBS, although originally unimodal, showed pronounced agglomeration on nebulization. With all polymers in water or glucose solution, the Zeta potential increases after nebulization, but with PBS as the carrier liquid the potential falls and is clearly associated with the observed agglomeration. Gel electrophoresis shows that the complexing polymers protect the DNA through the nebulization process in all cases.
Lynch
J
J
Department of Materials Science, University of Limerick, Limerick, Ireland.
Behan
N
N
Birkinshaw
Colin
C
D000818:Animals; D002021:Buffers; D004247:DNA / Q000737:chemistry* / Q000378:metabolism; D004587:Electrophoresis, Agar Gel; D018014:Gene Transfer Techniques; D015316:Genetic Therapy / Q000379:methods*; D005947:Glucose / Q000737:chemistry; D006801:Humans; D015394:Molecular Structure; D008970:Molecular Weight; D009330:Nebulizers and Vaporizers; D009690:Nucleic Acid Conformation; D009994:Osmolar Concentration; D010316:Particle Size; D011073:Polyamines; D000071228:Polyelectrolytes; D011094:Polyethyleneimine / Q000737:chemistry*; D011107:Polylysine / Q000737:chemistry*; D012140:Respiratory Tract Diseases / Q000235:genetics / Q000378:metabolism / Q000628:therapy*; D017550:Spectroscopy, Fourier Transform Infrared; D014867:Water / Q000737:chemistry
D002021:Buffers; D004247:DNA; D005947:Glucose; D011073:Polyamines; D000071228:Polyelectrolytes; D011094:Polyethyleneimine; D011107:Polylysine; D014867:Water; C427203:calf thymus DNA